STUDY SEARCH RESULTS

1 study found for your search request:  3475-992

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CR...
Condition: Urinary Bladder Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT04241185
Status: Recruiting
Has Enrolling Locations in US or Canada




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site